Search results for "BREAST"

showing 10 items of 1871 documents

Identification of Candidate Polymorphisms on Stress Oxidative and DNA Damage Repair Genes Related with Clinical Outcome in Breast Cancer Patients

2012

Diverse polymorphisms have been associated with the predisposition to develop cancer. On fewer occasions, they have been related to the evolution of the disease and to different responses to treatment. Previous studies of our group have associated polymorphisms on genes related to oxidative stress (rs3736729 on GCLC and rs207454 on XDH) and DNA damage repair (rs1052133 on OGG1) with a predisposition to develop breast cancer. In the present work, we have evaluated the hypothesis that these polymorphisms also play a role in a patient’s survival. A population-based cohort study of 470 women diagnosed with primary breast cancer and a median follow up of 52.44 months was conducted to e…

OncologyPathologyDNA Repairlcsh:ChemistryGenotypeMedicineProgesterone Receptor Negativegenetic variants; GCLC; XDH; OGG1; breast cancer; survivalOGG1lcsh:QH301-705.5SpectroscopyAged 80 and overeducation.field_of_studyGeneral MedicineMiddle AgedNeoplasm ProteinsComputer Science ApplicationsGCLCSurvival RateGCLCFemaleAdultmedicine.medical_specialtyPopulationBreast NeoplasmssurvivalArticleDisease-Free SurvivalCatalysisInorganic ChemistryBreast cancerbreast cancerMedian follow-upInternal medicineXDHHumansPhysical and Theoretical ChemistryeducationMolecular BiologyAgedPolymorphism GeneticProportional hazards modelbusiness.industrygenetic variantsOrganic ChemistryCancermedicine.diseaseOxidative Stresslcsh:Biology (General)lcsh:QD1-999businessDNA DamageFollow-Up StudiesInternational Journal of Molecular Sciences
researchProduct

Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2…

2012

Abstract Background: Previously, small studies have found that BRCA1 and BRCA2 breast tumors differ in their pathology. Analysis of larger datasets of mutation carriers should allow further tumor characterization. Methods: We used data from 4,325 BRCA1 and 2,568 BRCA2 mutation carriers to analyze the pathology of invasive breast, ovarian, and contralateral breast cancers. Results: There was strong evidence that the proportion of estrogen receptor (ER)-negative breast tumors decreased with age at diagnosis among BRCA1 (P-trend = 1.2 × 10−5), but increased with age at diagnosis among BRCA2, carriers (P-trend = 6.8 × 10−6). The proportion of triple-negative tumors decreased with age at diagnos…

OncologyPathologyendocrine system diseasesEpidemiologyGenes BRCA2Genes BRCA1Estrogen receptorGene mutation0302 clinical medicineCancer screeningMedicineskin and connective tissue diseasesEstrogen Receptor StatusOvarian Neoplasms0303 health sciencesMiddle Agedfemale genital diseases and pregnancy complications3. Good healthSerous fluidtriple-negative tumorsOncology030220 oncology & carcinogenesisFemaleestrogen receptorAdultmedicine.medical_specialtyBRCA1; BRCA2; breast cancer; estrogen receptor; triple-negative tumorsHereditary cancer and cancer-related syndromes Genetics and epigenetic pathways of disease [ONCOL 1]Breast NeoplasmsArticle03 medical and health sciencesbreast cancerBreast cancerSDG 3 - Good Health and Well-beingTranslational research [ONCOL 3]Internal medicineHumansGenetic Predisposition to DiseaseGenetics and epigenetic pathways of disease Translational research [NCMLS 6]Germ-Line MutationAged030304 developmental biologyHereditary cancer and cancer-related syndromes [ONCOL 1]business.industryCancerBRCA1medicine.diseaseBRCA2Neoplasm GradingbusinessOvarian cancer
researchProduct

PKP-004 Adverse events associated with Single Nucleotide Polymorphisms in breast cancer patients treated with docetaxel-based chemotherapy: Abstract …

2014

Background Inter-individual differences in drug response are linked, in many cases, to single nucleotide polymorphisms (SNPs) in genes coding for drug-metabolising enzymes and transporters. Docetaxel is active for several tumour types, including breast cancer, but its use is limited by toxicity. Purpose To evaluate the associations between a panel of 86 SNPs in 32 genes and toxicities developed by breast cancer patients treated with docetaxel. Materials and methods Between June 2011 and February 2013 breast cancer patients treated with docetaxel plus cyclophosphamide ± doxorubicin who gave informed consent were genotyped. Genomic DNA was analysed by a genetic analysis platform (MassArray, S…

OncologyPathologymedicine.medical_specialtyChemotherapyeducation.field_of_studyCyclophosphamidebusiness.industrymedicine.medical_treatmentPopulationSingle-nucleotide polymorphismmedicine.diseaseBreast cancerDocetaxelInternal medicinemedicineMucositisGeneral Pharmacology Toxicology and PharmaceuticsbusinesseducationAdverse effectmedicine.drugEuropean Journal of Hospital Pharmacy
researchProduct

Epulis-Like Presentation of Gingival Renal Cancer Metastasis

2017

Mouth metastatic cancers are very rare and they usually represent the evidence of a widespread disease. Common primary tumors are lung carcinoma in men and breast carcinoma in women, followed by kidney cancer. In the oral soft tissues, the gingiva is the most common site, suggesting a possible role of inflammation in the attraction of circulating tumor cells. Oral metastasis has a serious prognosis. In this work, we describe the case of a 58-year-old man affected by renal cancer, who was brought to our attention for the appearance of a gingival swelling. Initially, the lesion was excised through a provisional clinical diagnosis of epulis. Subsequently, anatomopathological analysis showed a …

OncologyPathologymedicine.medical_specialtyEpulisOphtalmologieCase Reportlcsh:RC254-282MetastasisMetastasis03 medical and health sciences0302 clinical medicineCirculating tumor cellClear-cell adenocarcinomaInternal medicineCarcinomamedicineClear-cell adenocarcinomaRiñones -- CáncerCell proliferationbusiness.industryOral cancerCancerMetástasisKidney cancer030206 dentistryCáncerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseBoca -- CáncerOncology030220 oncology & carcinogenesisbusinessBreast carcinomaKidney cancer
researchProduct

Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study

2009

Summary Background More accurate prognostic assessment of patients with neuroblastoma is required to better inform the choice of risk-related therapy. The aim of this study is to develop and validate a gene-expression signature to improve outcome prediction. Methods 59 genes were selected using an innovative data-mining strategy, and were profiled in the largest neuroblastoma patient series (n=579) to date using real-time quantitative PCR starting from only 20 ng of RNA. A multigene-expression signature was built using 30 training samples, tested on 313 test samples, and subsequently validated in a blind study on an independent set of 236 tumours. Findings The signature has a performance, s…

OncologyPediatricsmedicine.medical_specialtyMultivariate analysisbusiness.industryCase-control studyOdds ratiomedicine.diseaseBreast cancerOncologyNeuroblastomaInternal medicinemedicineStage (cooking)businessProspective cohort studySurvival analysisThe Lancet Oncology
researchProduct

The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials.

1998

Metastatic bone disease is a frequent cause of morbidity in advanced cancer patients with a subsequent high incidence of skeletal complications (fractures, hypercalcemia, spinal cord compression) and severe pain. The osteolytic process is mainly characterized by an osteoclastic activity of bone resorption and inflammatory activity provoked by various cytokines and prostaglandins. Bisphosphonates represent a new class of drugs with inhibitory activity on bone resorption and on inflammatory processes which revealed themselves to be efficacious in a series of clinical conditions such as tumour-induced hypercalcemia, Paget's disease, osteoporosis and metastatic bone disease. The aim of this rev…

OncologyQuality of lifemedicine.medical_specialtyBone diseaseOsteoporosisBone NeoplasmsBone resorptionMetastasisBreast cancerSpinal cord compressionInternal medicinemedicineBisphosphonateHumansCancer painMultiple myelomaPalliative therapyDiphosphonatesbusiness.industryPalliative Caremedicine.diseaseSurgeryBone metastaseAnesthesiology and Pain MedicineNeurologyClinical Trials Phase III as TopicNeurology (clinical)Randomized trialbusinessCancer painPainReferences
researchProduct

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a r…

2018

Background: Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, exemestane, and letrozole. We investigated the schedule and type of aromatase inhibitors to be used as adjuvant treatment for hormone receptor-positive early breast cancer. Methods: FATA-GIM3 is a multicentre, open-label, randomised, phase 3 trial of six different treatments in postmenopausal women with hormone receptor-positive early breast cancer. Eligible patients had histologically confirmed invasive hormone receptor-positive breast cancer that had been completely remov…

OncologyReceptor ErbB-2Settore MED/06 - Oncologia Medicaletrozolelaw.inventionAdjuvant anastrozolechemistry.chemical_compound0302 clinical medicineRandomized controlled trialExemestanelawAdjuvant anastrozole; exemestane; letrozole; tamoxifen; breast cancerAntineoplastic Combined Chemotherapy Protocols030212 general & internal medicinetamoxifenAromatase InhibitorsLetrozoleHazard ratioMiddle AgedReceptors EstrogenTolerabilityOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleReceptors ProgesteroneBreast NeoplasmHumanmedicine.drugmedicine.medical_specialtySocio-culturaleAnastrozoleBreast NeoplasmsAnastrozoleDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesBreast cancerbreast cancerInternal medicinemedicineAromatase InhibitorHumansAgedAntineoplastic Combined Chemotherapy ProtocolAndrostadienebusiness.industrymedicine.diseaseAndrostadieneschemistrybusinessexemestaneTamoxifen
researchProduct

Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women.

2004

BACKGROUND Genes encoding enzymes involved in estrogen metabolism are held to be candidate genes for associations with breast disease. In these candidate genes, no critical combination of single-nucleotide polymorphisms (SNPs) for assessing breast carcinoma risk has been reported to date. METHODS In a large case–control study, the authors investigated 10 estrogen-metabolizing SNPs in 396 patients with breast carcinoma, 154 patients with fibroadenoma, and 1936 healthy control patients without breast carcinoma in their personal history. The following 10 SNPs were analyzed using sequencing-on-chip technology via a solid-phase polymerase chain reaction assay performed on oligonucleotide microar…

OncologyRiskCancer Researchmedicine.medical_specialtyCandidate geneSingle-nucleotide polymorphismBreast NeoplasmsPolymorphism Single NucleotideWhite PeopleGene FrequencyInternal medicineGenotypeCarcinomaCytochrome P-450 CYP1A1MedicineHumansGenetic Predisposition to Diseasebusiness.industryCarcinomaCancerSteroid 17-alpha-HydroxylaseEstrogensMiddle Agedmedicine.diseaseFibroadenomaEndocrinologyOncologyFibroadenomaCase-Control StudiesFemaleBreast diseasebusinessBreast carcinomaCancer
researchProduct

The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis

2017

Introduction: Tamoxifen is a selective estrogen receptor modulator widely used in the treatment of breast cancer. Tamoxifen therapy is associated with reduced circulating low-density lipoprotein cholesterol and increased triglycerides, but its effects on other lipids are less-well studied. Aims: We aimed to investigate the effect of tamoxifen on circulating concentrations of lipoprotein(a) (Lp(a)) through systematic review and meta-analysis of available randomized controlled trials (RCTs) and observational studies. Methods: This study was registered in the PROSPERO database (CRD42016036890). Scopus, Medline and EMBASE were searched from inception until 22nd March 2016 to identify studies in…

OncologySelective Estrogen Receptor Modulatorsmedicine.medical_specialtyRMTamoxifen; lipoprotein(a) concentration; circulation; treatmentBreast Neoplasms030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicineBreast cancerRandomized controlled triallawInternal medicineCell Line TumormedicineHumansPharmacology (medical)QDRandomized Controlled Trials as Topictreatmentbusiness.industrymedicine.diseaselipoprotein(a) concentrationConfidence intervalTamoxifenEndocrinologyStrictly standardized mean differenceSelective estrogen receptor modulator030220 oncology & carcinogenesisMeta-analysiscirculationFemaleSystematic ReviewbusinessTamoxifenmedicine.drugLipoproteinLipoprotein(a)
researchProduct

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial

2019

Abstract Background The 8th edition of the American Joint Committee on Cancer (AJCC) staging has introduced prognostic stage based on anatomic stage combined with biologic factors. We aimed to validate the prognostic stage in HER2-positive breast cancer patients enrolled in the ShortHER trial. Methods The ShortHER trial randomized 1253 HER2-positive patients to 9 weeks or 1 year of adjuvant trastuzumab combined with chemotherapy. Patients were classified according to the anatomic and the prognostic stage. Distant disease-free survival (DDFS) was calculated from randomization to distant relapse or death. Results A total of 1244 patients were included. Compared to anatomic stage, the prognost…

OncologySettore MED/06 - Oncologia Medicamedicine.medical_treatmentlcsh:MedicineAntineoplastic Agents Immunological0302 clinical medicineBreast cancerTrastuzumabAntineoplastic Combined Chemotherapy Protocols8th AJCC030212 general & internal medicineStage (cooking)8th AJCC; Breast cancer; HER2-positive; Prognostic stage; TrastuzumabGeneral MedicineMiddle AgedPrognosisImmunologicalLocal030220 oncology & carcinogenesisFemaleResearch Articlemedicine.drugAdultmedicine.medical_specialtyRandomizationSocio-culturaleAntineoplastic AgentsBreast NeoplasmsDisease-Free Survival03 medical and health sciencesBreast cancerInternal medicinePrognostic stagemedicineAdjuvant therapyHumanserbB-2AgedNeoplasm StagingCancer stagingChemotherapybusiness.industrylcsh:RCancerGenes erbB-2Trastuzumabmedicine.diseaseHER2-positive Breast cancer Trastuzumab Prognostic stage 8th AJCCHER2-positiveNeoplasm RecurrenceGenesNeoplasm Recurrence Localbusiness
researchProduct